^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EGFR (Epidermal growth factor receptor)

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    1d
    Pathogenic Variants in Genes Associated With Lung Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=332, Recruiting, Oscar Gerardo Arrieta Rodríguez | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    MET exon 14 mutation
    1d
    A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) (clinicaltrials.gov)
    P2, N=147, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2026 --> Feb 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    1d
    ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (clinicaltrials.gov)
    P=N/A, N=140, Completed, AstraZeneca | Recruiting --> Completed | N=105 --> 140
    Trial completion • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
    |
    MSI-H/dMMR • BRAF mutation • HER-2 expression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    1d
    Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Ivesa (firmonertinib)
    1d
    C6461004: A Study to Learn about the Study Medicine called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive Stage Small Cell Lung Cancer (2025-523522-41-00)
    P2/3, N=47, Not yet recruiting, Pfizer Inc.
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV
    1d
    Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    1d
    TCOG T1521: The Research Plan of Taiwan Precision Medicine (clinicaltrials.gov)
    P=N/A, N=550, Recruiting, National Health Research Institutes, Taiwan | Trial primary completion date: Dec 2025 --> Dec 2030
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    2d
    GDPD5-CD55-EGFR competitive binding axis regulates radioresistance and lipid accumulation in rectal cancer. (PubMed, Cell Death Dis)
    Our findings indicate that GDPD5 facilitates EGFR nuclear translocation by binding to CD55, suppressing p53, and causing lipid accumulation and radiotherapy resistance in tumors. Targeting the GDPD5-CD55-EGFR interaction may enhance radiosensitivity.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CD55 (CD55 Molecule)
    2d
    Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol. (PubMed, BMJ Open)
    This scoping review will rely exclusively on the collection and analysis of published and/or publicly available sources; therefore, ethical approval is not required. The findings will be disseminated through publication in peer-reviewed journals, presentation at scientific conferences and via digital science communication platforms.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    2d
    Strategic characterization of active pharmaceutical ingredients co-eluting impurities: Identification, enrichment and structural elucidation of an oxidized impurity from mobocertinib drug substance. (PubMed, J Pharm Biomed Anal)
    Following isolation by prep-HPLC, 1D and 2D NMR studies and HRMS characterization assigned the isolate as Mobocertinib-N-oxide. In addition, NMR-based reaction monitoring was conducted to trace its formation, allowing a plausible mechanism of formation to be proposed.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation
    |
    Exkivity (mobocertinib)
    2d
    EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer. (PubMed, J Clin Invest)
    Izalontamab brengitecan (Iza-bren; BL-B01D1) is a bispecific ADC targeting EGFR and HER3 that has demonstrated activity in other malignancies. Importantly, tumor tissue obtained at progression after BL-B01D1 treatment confirmed ABCG2 upregulation, validating a clinically relevant resistance mechanism. These findings support BL-B01D1 as a promising therapeutic strategy in mCRPC and nominate ABCG2 as a rational target for overcoming resistance.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    EGFR expression
    |
    izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    2d
    Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy. (PubMed, J Formos Med Assoc)
    The worse prognoses and limited treatment options for patients with advanced NSCLC harboring EGFR ex20ins from the Taiwan real-world setting indicate an urgent need for effective treatment for this population. This study showed that amivantamab, when administrated in the CHRYSALIS trial setting, represents a promising treatment option for patients compared to current real-world therapies.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation